168 related articles for article (PubMed ID: 26308378)
1. ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.
Krakstad C; Tangen IL; Hoivik EA; Halle MK; Berg A; Werner HM; Ræder MB; Kusonmano K; Zou JX; Øyan AM; Stefansson I; Trovik J; Kalland KH; Chen HW; Salvesen HB
Oncotarget; 2015 Sep; 6(29):28440-52. PubMed ID: 26308378
[TBL] [Abstract][Full Text] [Related]
2. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.
Kalashnikova EV; Revenko AS; Gemo AT; Andrews NP; Tepper CG; Zou JX; Cardiff RD; Borowsky AD; Chen HW
Cancer Res; 2010 Nov; 70(22):9402-12. PubMed ID: 20864510
[TBL] [Abstract][Full Text] [Related]
3. ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection.
Hwang HW; Ha SY; Bang H; Park CK
Cancer Res Treat; 2015 Oct; 47(4):853-61. PubMed ID: 25687855
[TBL] [Abstract][Full Text] [Related]
4. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.
Raeder MB; Birkeland E; Trovik J; Krakstad C; Shehata S; Schumacher S; Zack TI; Krohn A; Werner HM; Moody SE; Wik E; Stefansson IM; Holst F; Oyan AM; Tamayo P; Mesirov JP; Kalland KH; Akslen LA; Simon R; Beroukhim R; Salvesen HB
PLoS One; 2013; 8(2):e54873. PubMed ID: 23393560
[TBL] [Abstract][Full Text] [Related]
5. ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker.
Zhang M; Zhang C; Du W; Yang X; Chen Z
Clin Transl Oncol; 2016 Aug; 18(8):776-81. PubMed ID: 26527032
[TBL] [Abstract][Full Text] [Related]
6.
Wang C; Yin Y; Sun Z; Wang Y; Li F; Wang Y; Zhang Z; Chen X
Dis Markers; 2022; 2022():2334338. PubMed ID: 36479043
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis.
Shang P; Meng F; Liu Y; Chen X
Tumour Biol; 2015 Jun; 36(6):4479-85. PubMed ID: 25934333
[TBL] [Abstract][Full Text] [Related]
8. Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signaling.
Lu WJ; Chua MS; So SK
Oncotarget; 2015 Dec; 6(39):41722-35. PubMed ID: 26497681
[TBL] [Abstract][Full Text] [Related]
9. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.
Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J
Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476
[TBL] [Abstract][Full Text] [Related]
10. A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma.
Fouret R; Laffaire J; Hofman P; Beau-Faller M; Mazieres J; Validire P; Girard P; Camilleri-Bröet S; Vaylet F; Leroy-Ladurie F; Soria JC; Fouret P
Clin Cancer Res; 2012 Oct; 18(20):5606-16. PubMed ID: 22914773
[TBL] [Abstract][Full Text] [Related]
11. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
12. High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
Wik E; Birkeland E; Trovik J; Werner HM; Hoivik EA; Mjos S; Krakstad C; Kusonmano K; Mauland K; Stefansson IM; Holst F; Petersen K; Oyan AM; Simon R; Kalland KH; Ricketts W; Akslen LA; Salvesen HB
Clin Cancer Res; 2013 May; 19(9):2331-41. PubMed ID: 23538402
[TBL] [Abstract][Full Text] [Related]
13. Expression of proliferation genes in formalin-fixed paraffin-embedded (FFPE) tissue from breast carcinomas. Feasibility and relevance for a routine histopathology laboratory.
Thomas C; Robinson C; Dessauvagie B; Wood B; Sterrett G; Harvey J; Amanuel B
J Clin Pathol; 2017 Jan; 70(1):25-32. PubMed ID: 27235535
[TBL] [Abstract][Full Text] [Related]
14. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
Noske A; Brandt S; Valtcheva N; Wagner U; Zhong Q; Bellini E; Fink D; Obermann EC; Moch H; Wild PJ
Oncotarget; 2017 Feb; 8(9):14794-14805. PubMed ID: 27582547
[TBL] [Abstract][Full Text] [Related]
15. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
Liu Q; Liu H; Li L; Dong X; Ru X; Fan X; Wen T; Liu J
Int J Oncol; 2020 Jan; 56(1):219-231. PubMed ID: 31746426
[TBL] [Abstract][Full Text] [Related]
16. [Expression of ATAD2 in different liver lesions and its clinical significance].
Liu F; Zhou X; Ji HH; Li H; Xiang FG
Zhonghua Gan Zang Bing Za Zhi; 2017 May; 25(5):339-343. PubMed ID: 28763839
[No Abstract] [Full Text] [Related]
17. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
Engelsen IB; Stefansson IM; Beroukhim R; Sellers WR; Meyerson M; Akslen LA; Salvesen HB
Int J Oncol; 2008 Feb; 32(2):307-16. PubMed ID: 18202752
[TBL] [Abstract][Full Text] [Related]
18. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
19. Differential gene expression profiling of gastric intraepithelial neoplasia and early-stage adenocarcinoma.
Xu X; Feng L; Liu Y; Zhou WX; Ma YC; Fei GJ; An N; Li Y; Wu X; Yao F; Cheng SJ; Lu XH
World J Gastroenterol; 2014 Dec; 20(47):17883-93. PubMed ID: 25548486
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses.
Bredholt G; Mannelqvist M; Stefansson IM; Birkeland E; Bø TH; Øyan AM; Trovik J; Kalland KH; Jonassen I; Salvesen HB; Wik E; Akslen LA
Oncotarget; 2015 Nov; 6(37):39676-91. PubMed ID: 26485755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
